Scarica l'app Stockscreener
18.50
2.43%
-0.46
Dopo l'orario di chiusura:
18.55
0.05
+0.27%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GLUE Giù?
Forum
Previsione
Monte Rosa Therapeutics Inc Borsa (GLUE) Ultime notizie
Monte Rosa Therapeutics, Inc. Announces Executive Changes, Effective April 3, 2026 - marketscreener.com
Smart Money: How sensitive is Monte Rosa Therapeutics Inc to inflationEarnings Growth Report & Technical Buy Zone Confirmations - baoquankhu1.vn
3 High-Risk Stocks That Soared in 2025 But Can Still Fly Higher - Investing.com
Monte Rosa Therapeutics, Inc.'s (NASDAQ:GLUE) institutional investors lost 12% last week but have benefitted from longer-term gains - Yahoo Finance
Zacks Research Downgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Hold - MarketBeat
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Spikes: Is Monte Rosa Therapeutics Inc stock a good pick for beginnersBuy Signal & Weekly High Conviction Trade Ideas - baoquankhu1.vn
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Sees Large Drop in Short Interest - MarketBeat
Winners Losers: Can Monte Rosa Therapeutics Inc ride the EV waveWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Monte Rosa Therapeutics Inc. subject to activist investor interestPortfolio Profit Report & Daily Entry Point Trade Alerts - mfd.ru
Promising Small Cap Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics (NASDAQ:GLUE) Trading Down 6.9%What's Next? - MarketBeat
Aug Volume: What are Monte Rosa Therapeutics Incs earnings expectationsIPO Watch & Detailed Earnings Play Strategies - baoquankhu1.vn
Aug Gainers: Is Monte Rosa Therapeutics Inc stock a hidden gemJuly 2025 Earnings & Weekly High Potential Stock Alerts - baoquankhu1.vn
51,133 Shares in Monte Rosa Therapeutics, Inc. $GLUE Bought by Campbell & CO Investment Adviser LLC - MarketBeat
Biotech Stocks To Add to Your WatchlistJanuary 7th - MarketBeat
Monte Rosa Therapeutics announces pricing of $300M stock offering - MSN
Short Interest in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Rises By 20.7% - MarketBeat
Goodwin Guides Monte Rosa Therapeutics In Pricing Of $300 Million Underwritten Public Offering - Mondaq
The Bull Case For Monte Rosa Therapeutics (GLUE) Could Change Following MRT-8102 Data And $300 Million Raise - Sahm
Monte Rosa Therapeutics (GLUE) Price Target Increased by 30.77% to 28.49 - Nasdaq
Aug Highlights: Does Monte Rosa Therapeutics Inc stock trade at a discount to peersWeekly Trend Report & High Return Stock Watch Alerts - Bộ Nội Vụ
Assessing Monte Rosa Therapeutics (GLUE) Valuation After Strong MRT-8102 Phase 1 Data And Share Price Momentum - Yahoo Finance
How institutional buying supports Monte Rosa Therapeutics Inc. stockJuly 2025 Highlights & Daily Market Momentum Tracking - Улправда
Latham & Watkins Advises on Monte Rosa Therapeutics’ US$300 Million Underwritten Public Offering - Latham & Watkins LLP
Insider Sell: Markus Warmuth Sells Shares of Monte Rosa Therapeu - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) CEO Markus Warmuth Sells 5,466 Shares - MarketBeat
Monte Rosa Therapeutics Signs Underwriting Agreement With Jefferies, TD Securities and Piper Sandler - TradingView — Track All Markets
Finance Watch: Aktis Tests 2026 IPO Waters With Year’s First Offering, Raising $318m - Citeline News & Insights
Monte Rosa Therapeutics (GLUE) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Monte Rosa Therapeutics Prices Underwritten Public Offering Of $300 Mln Of Shares - Nasdaq
Why Monte Rosa Therapeutics Inc. stock is considered a top pickWeekly Investment Recap & Risk Managed Investment Strategies - ulpravda.ru
Monte Rosa Therapeutics prices $300 million public offering By Investing.com - Investing.com South Africa
Monte Rosa Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Monte Rosa Therapeutics prices $300 million public offering - Investing.com
Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering - Yahoo Finance
Biotech Monte Rosa is selling $300M in new shares to investors - Stock Titan
Monte Rosa Therapeutics announces pricing of $300 million underwritten public offering at $24.00 per share - marketscreener.com
Can Monte Rosa Therapeutics Inc. stock beat analyst upgradesJuly 2025 Highlights & AI Forecasted Stock Moves - ulpravda.ru
GLUE Stock: Guggenheim Maintains Buy Rating, Raises Price Target - GuruFocus
Will Monte Rosa Therapeutics Inc. stock attract more institutional investorsWeekly Investment Summary & Free AI Powered Buy and Sell Recommendations - Улправда
Is Monte Rosa Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Snapshot & Accurate Buy Signal Notifications - ulpravda.ru
GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug - Finviz
Why Monte Rosa Therapeutics Inc. stock is a must watch in 2025Weekly Profit Summary & Community Trade Idea Sharing - ulpravda.ru
Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says - MarketBeat
GLUE Stock Receives Analyst Rating Update with Raised Price Targ - GuruFocus
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $34.00 Price Target at Guggenheim - MarketBeat
Monte Rosa Therapeutics: Competitive MRT-8102 Results Offer Additional Platform Validation - Seeking Alpha
Monte Rosa Therapeutics Reaches Analyst Target Price - Nasdaq
Monte Rosa Therapeutics dips after $200 mln equity offering launched - TradingView — Track All Markets
Zacks Research Upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) to Strong-Buy - MarketBeat
Monte Rosa Therapeutics launches $200 million public offering By Investing.com - Investing.com Nigeria
1.24%
0.19%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):